Background:\rDelivery of anticancer drugs in vivo can be achieved by using targetspecific\rdrug carriers of various types – e.g. microspheres and liposomes –\rwhich can be applied intravenously, or subcutaneously via a hypodermal\rpatch, etc. as appropriate to the type of drug carrier employed. Recently,\rinterest has surged in the usage of amphiphilic polymeric micelles for this\rpurpose, as they prove superior to other drug carriers in many ways. They\rhave highly-hydrated hydrophilic shells, and hydrophobic cores wherein\rhydrophobic anticancer drugs such as adriamycin can be encapsulated\rduring transport in the blood. Their main advantages include their\rsmallness of size – enabling them to elude capture by the\rreticuloendothelial system (RES) – their stability in the bloodstream as\rshown in their low critical micelle concentration (CMC) values, their\rpassive targeting of tumour sites via the enhanced permeability and\rretention (EPR) effect, and their ability to integrate an active targeting\rmechanism, e.g. antibody-antigen recognition, pH-sensitivity, etc.